|Budget Amount *help
¥19,240,000 (Direct Cost: ¥14,800,000、Indirect Cost: ¥4,440,000)
Fiscal Year 2011: ¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2010: ¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2009: ¥8,840,000 (Direct Cost: ¥6,800,000、Indirect Cost: ¥2,040,000)
Our aim is to construct accurate screening system for pharmacokinetics(PK) to uncover genetic loci associate with drug responsiveness such as side effects or responder/non-responder. Genes related to PK well known to recognize high homology within superfamily, simultaneous amplification of different genomic regions in one test is causes of incorrect genotyped, incorrect sequence, and a fatal mistake in diagnosis. We identified all variations in 28 genes encoding drug metabolizing enzymes and drug transporters, CYP1A2, CYP2A6, CYP2C8, CYP2C18, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, OAT1, OAT2, OAT3, OCT1, OCT2, OCTN1, OCTN2, OATP1, OATP2, MATE1, MATE2, MRP1, MRP2, MDR1, PEPT1, PEPT2, PMAT, TPMT, and UGT1A1, recognized high homology in different regions, based on the combination the pair-end method of Next Generation Sequencer with an internally developed target specific long PCR system. In addition, we constructed a routine genotyping system of almost short variations(94%) based on combination Invader method and the long PCR. We planning to perform the routine screening in collaboration with other researchers focus on drug responsiveness.